Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250509 | 1.00 | F2 (0.52) | F2HGFACTP53MAPTALOX5 | |
| SCHEMBL4250502 | 1.00 | F2 (0.52) | F2HGFACTP53MAPTALOX5 | |
| SCHEMBL4253707 | 0.82 | GAA (0.51) | HGFACMAPTALDH1A1CES2CES1 | |
| SCHEMBL4258068 | 0.82 | GAA (0.51) | HGFACMAPTALDH1A1CES2CES1 | |
| SCHEMBL4253701 | 0.82 | GAA (0.51) | HGFACMAPTALDH1A1CES2CES1 | |
| SCHEMBL11195246 | 0.80 | F2 (0.61) | F2HGFACTP53MAPTALOX5 | |
| SCHEMBL2955782 | 0.78 | F2 (0.63) | F2HGFACTP53MAPTALOX5 | |
| SCHEMBL7929197 | 0.78 | F2 (0.63) | F2HGFACTP53MAPTALOX5 | |
| SCHEMBL4246726 | 0.77 | ALDH1A1 (0.50) | F2HGFACMAPTALOX5LMNA | |
| SCHEMBL4246720 | 0.77 | ALDH1A1 (0.50) | F2HGFACMAPTALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2105431-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105432-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-1867626-A2 | Process for producing chromone compound | Sumitomo Chemical Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20060217565-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7094914-B2 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20050085664-A1 | Process for producing chromone compound | SUMITOMO CHEMICAL COMPANY, LMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1479667-A1 | PROCESS FOR PRODUCING CHROMONE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085664-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | F2 352/4885HGFAC 3965/4885TP53 2582/4885 |
| US-20060217565-A1 | Process for producing chromone compound | ENY2, CDY1; CDY1B, CDYL | F2 352/4885HGFAC 3965/4885TP53 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.